Cargando…
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
This study investigated the “real-world” use of ranibizumab for neovascular age-related macular degeneration (nAMD) in Taiwan and assessed the visual outcome. We reviewed the medical records at National Cheng Kung University Hospital, Taiwan, during 2012–2014 for 264 consecutive eyes of 229 patients...
Autores principales: | Chang, Yi-Sheng, Lee, Wan-Ju, Lim, Chen-Chee, Wang, Shih-Hao, Hsu, Sheng-Min, Chen, Yi-Chian, Cheng, Chia-Yi, Teng, Yu-Ti, Huang, Yi-Hsun, Lai, Chun-Chieh, Tseng, Sung-Huei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945845/ https://www.ncbi.nlm.nih.gov/pubmed/29748599 http://dx.doi.org/10.1038/s41598-018-25864-0 |
Ejemplares similares
-
Ranibizumab in neovascular age-related macular degeneration
por: Eng, Kenneth T, et al.
Publicado: (2006) -
Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008) -
Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration
por: Rotsos, Tryfon, et al.
Publicado: (2010) -
The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
por: Brown, Gary C., et al.
Publicado: (2017) -
Ranibizumab port delivery system in neovascular age-related macular degeneration
por: Chandrasekaran, Priya R., et al.
Publicado: (2022)